ORYZON

Pioneering Personalized Medicine in

EPIGENETICS

CORPORATE PRESENTATION
2Q-2020

Legal Notice

DISCLAMER This document has been prepared by Oryzon Genomics, S.A. exclusively for use during the presentation. Oryzon Genomics, S.A. does not assume liability for this document if it is used with a purpose other than the above. The information and any opinions or statements made in this document have not been verified by independent third parties; therefore, no express or implied warranty is made as to the impartiality, accuracy, completeness or correctness of the information or the opinions or statements expressed herein. Oryzon Genomics, S.A. does not assume liability of any kind, whether for negligence or any other reason, for any damage or loss arising from any use of this document or its contents. Neither this document nor any part of it constitutes a contract, nor may it be used for incorporation into or construction of any contract or agreement. Information in this document about the price at which securities issued by Oryzon Genomics, S.A. have been bought or sold in the past or about the yield on securities issued by Oryzon Genomics, S.A. cannot be relied upon as a guide to future performance.

IMPORTANT INFORMATION This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of Law 24/1988, of 28 July, on the Securities Market, Royal Decree-Law 5/2005, of 11 March, and/or Royal Decree 1310/2005, of 4 November, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.

FORWARD-LOOKING STATEMENTS This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Oryzon Genomics, S.A. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This presentationis not an offer of securities for sale in the United States. The Company’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company’s securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

Company Highlights

- A **clinical stage** biopharmaceutical company developing innovative therapies in the field of **Epigenetics**
- **Two molecules** already with **positive data in humans**
- Large IP portfolio with technology fully developed in-house
- MADX: ORY A **publicly traded** company on the **Spanish Stock Exchange**
- Integrated in the **IBEX Small Cap Index**

- **Raised an aggregate of circa €85M** (in 2015-2019)
- **Cash runway** expected till **1Q2022**
- One of the most **LIQUID** companies in the MicroCap group in the Spanish Stock Market
  - 45.7 M Shares outstanding. Fully diluted
  - +310,000 daily volume (Avg Traded Volume in 2019)
  - +78M shares negotiated in 2019 / ≈6 months for share full turnover

BOLSA DE MADRID

IBEX Small Cap

ORYZON GENOMICS SA
BALANCE SHEET DATA (UNAUDITED)
(Amounts in thousands US $)

	March 31st, 2020	March 31st, 2019
Cash and cash equivalents	32,121	32,551
Marketable securities	155	159
Total Assets	84,301	73,158
Deferred revenue	0	0
Total Stockholders' equity	65,709	49,240

[1] *Spanish GAAPs*

Epigenetic Modifications: New Targets for Drug Development



Figure from Arrowsmith et al. *Nature Reviews Drug Discovery* **volume 11** (2012)

- **Heritable DNA modifications that do not alter the actual DNA sequence but change gene activity and expression**
  - **Histone modifications**
  - **DNA methylation**
  - **microRNAs…**
- **Histone modifying enzymes are "writers" or "erasers" - adding or removing epigenetic marks from histone tails**
- **Epigenetic dysfunctions are associated with aberrant gene expression and disease**
- **Epigenetic drugs can restore these transcriptional imbalances**

An area of hot world class science

Lysine specific histone demethylase 1 (LSD1): an epigenetic "eraser" that removes methyl groups from histones

LSD1 expression and activity can both block and promote gene expression

LSD1 plays a important role in cancer, CNS, inflammatory and viral diseases

Oryzon is pioneering epigenetics in CNS and active in oncology

A broad pipeline to address unmet medical needs with an attractive market opportunity



CNS Market Need

Aggression is a common feature in many psychiatric diseases. +50% in ADHD(**)

Global BPD market expected to grow to $2.6B in 2027

45 million people with AD worldwide; 20% shows aggresiveness

Options to accelerated approval in genetic subpopulations of schizophrenia and ASD

Oncology Market Need

Global AML market of $990m in 2019. Room for new Combos according to KoLs

SCLC is a serious unmet medical need, with a MOS of 8–12 months and 5% 2-year OSR

Global SCLC market +300,000 patients/y. FDA approved label extension of Pembro but only 19% of ORR (***)

Options to accelerated approval in subpopulations of AML-MDS

(**) J Child Adolesc Psychopharmacol. 2016 Feb 1; 26(1): 19–25.
(***) Keynote study in 83 patients

ORYZON

VAFIDEMSTAT a Phase II Clinical Stage Compound with a broad developability in CNS diseases

Vafidemstat (ORY-2001): a “Neuron-fixer” ready for Phase IIb

- Vafidemstat is a **small molecule** LSD1 inhibitor optimized for CNS
- **Excellent Pharmacology**. High **oral** bioavailability
- **Positive** results in **7 different animal models** and in i*n-vitro* models
  - Cognition
  - Neuroprotection
  - Neuroinflammation
  - Social Withdrawal / Apathy
  - Aggression / Agitation
  - Others
- Epigenetic **MoA** that modulates **neuroinflammation** and expression of key **plasticity neuronal genes**
- Biomarkers identified
- **Good Safety in humans in Phase I+II trials with about 250 participants** so far
- **BBB penetrance** and (indirect) human brain target engagement established
- Pharmacologically active in humans

Vafidemstat, and LSD1 inhibition, improves cognition

In Alzheimer's SAMP8 model vafidemstat restores memory by the NORT model	In **Huntington disease** R6/1 model vafidemstat improves memory by the NORT model	In **Schizophrenia** SETD1a +/- model iadademstat (ORY-1001) improves working memory	In **Psychosis & Schizophrenia** NMDA receptor-hypofunction mice model T-448 (TAKEDA) LSD1 inhibitor improves memory

Vafidemstat Fully Restores Memory Measured by NORT in SAMP8 AD Model



Cognition and memory impairments are found in AD and dementias but also in Autism, Schizophrenia, Depression, Bipolar disorder and other psychiatric conditions

Vafidemstat Produces Significant Behavioural Changes

Vafidemstat Reduces Aggression in the Resident Intruder Test in the SAMP8 AD Mice model

Vafidemstat Enhances Sociability in the Three-Chamber Test in SAMP8 AD Mice



Vafidemstat Reduces Social Withdrawal in the Rat Isolation Model



MoA: an upstream epigenetic mechanism producing a dual activity, antinflammatory and prosynaptic

LSD1 localizes *in vivo* to enhancers and promoters of confirmed CNS disease risk genes

LSD1 binds to TFs that control IEG expression and stress in the PFC-amygdala axis, including SRF

- Vafidemstat **up-regulates** genes associated with **Neuroplasticity & Cognition**
- Vafidemstat **reduces** the expression of **inflammatory** genes as S100A9 and others in SAMP8 AD model and IL-6, IL-1B and many others in MS models



LSD1 inhibition rescues different phenotypes in genetic models of ASD and Schizophrenia

nature neuroscience

Article | Published: 12 March 2018

Social deficits in *Shank3*-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition

Luye Qin, Kaijie Ma, Zi-Jun Wang, Zihua Hu, Emmanuel Matas, Jing Wei & Zhen Yan



Image from Yi et al *Science* 06 May 2016

Mutation of SHANK3 gene is causally linked to ASD. HDAC & LSD1 inhib rescue the mice phenotype Qin et al Nat Neurosci. 2018. & Zhen Yan Oral Comm SF-2019



LSD1 inhibition also rescues the Shank3 ASD phenotype

Zhen Yan *Oral Comm* SFN-2019



Neuron

Recapitulation and Reversal of Schizophrenia-Related Phenotypes in *Setd1a*-Deficient Mice

Jun Mukai [7, 8] • Enrico Cannavò [7] • Gregg W. Crabtree • ... Atsushi Takata • Bin Xu • Joseph A. Gogos [9, 10] • Show all authors • Show footnotes

Published: October 09, 2019 • DOI: https://doi.org/10.1016/j.neuron.2019.09.014



LSD1 inhibition rescues the contralateral axon branching deficits in-vivo in the Setd1a $^{+/-}$mice



Rescue of WM performance in Setd1a+/- mice treated with ORY-1001



LSD1 inhibition paves the way for personalized medicine in psychiatry

- SETD1A is a key schizophrenia (SCZ) susceptibility gene. Mutations in SETD1A increase the risk of SCZ by 35 times, as well as a number of other neurological disorders. SETD1A is part of the Set1/COMPASS complex, mediates mono-, di-, and tri-methylation of the lysine 4 on the histone H3 protein
- In addition to SETD1A, mutations in other subunits of Set1/COMPASS complex have been reported in SCZ and other neuro-developmental disorders
- Mutant mice carrying a heterozygous loss-of-function mutation of the orthologous gene exhibit alterations in axonal branching and cortical synaptic dynamics, accompanied by specific deficits in working memory that recapitulate SCZ-related alterations
- SCZ patients carrying these mutations identified.
- Increased interest by FDA and other regulators to explore a personalized medicine approach in these hard to treat populations



Vafidemstat : Safety demonstrated in 250 volunteers and patients

Safe and well tolerated in a +100 healthy volunteers (young and elderly) Phase I (MAD+SAD) study

- No hematological impact at planned doses
- Efficiently crossed the BBB (70-90%)
- Oral PK - Half Life of 22h allowing once daily oral
- PK/PD data allowed definition of recommended Phase II doses

Safe and well tolerated so far in diverse Phase II studies

- Vafidemstat has been already administered to around 250 volunteers and patients
- Phase IIs (MS, AD, ADHD, BPD and ASD patients) with no safety signals to date
- Longest exposure to date: 18 months

Vafidemstat: REIMAGINE - a Basket trial in aggression

Duration	8 Weeks treatment + 4 weeks of follow up		
Cohorts to be recruited			
Borderline Personality Disorder	6 patients	Done – Data reported in April 2019	Upscaled later to an aggregated of 30 patients; **Trial Status Completed (LPO 22.10.2019)**
Attention Deficit and Hyperactivity Disorder	6 patients	Done – Data reported in April 2019	
Autism Spectrum Disorder	6 patients	Done – Data reported in Sept 2019	

Endpoints

Safety

Efficacy:

Aggression / Agitation measured by CGI-S

Aggression / Agitation measured by CGI-I

Aggression / Agitation measured by NPI A/A 4 items

Psychiatric status measured by NPI Global assessment (12 items)

Change in specific disease scales

Significant improvements in aggression evaluated using the Neuropsychiatric Inventory 4-item agitation/aggression score **(NPI-A/A)**



Reduced Aggressivity in patients of the three psychiatric indications: Borderline Personality Disorder (BPD), Attention Deficit and Hyperactivity Disorder (ADHD) and Autistic Spectrum Disorder (ASD) treated with vafidemstat

REIMAGINE data presented at

EPA 2019 27TH EUROPEAN CONGRESS OF PSYCHIATRY

7th World Congress on ADHD

32ND ECNP CONGRESS

CINP 2019 CINP International Meeting

REIMAGINE-AD: Reduction of agitation/aggression in severe and moderate AD patients after 6 months

REIMAGINE-AD: A Phase IIa trial in Moderate and Severe AD		
Duration	**24 weeks treatment + 4 weeks of follow up**	
Open Label / Single arm (1.2mg)	12 patients	Recruitment Completed

- Statistical improvements in different Agitation/Aggression scales after 6 months of treatment: CGI-I, CMAI and NPI-A/A
- Reduction on Agitation / agression takes longer in severe and moderate AD patients than in younger REIMAGINE patients
- Also improvements in Caregiver burden and Global NPI



Data Presented at APRIL 2020

AD/PD™2020 The 15th International Conference on Alzheimer's & Parkinson's Diseases

Next steps: The company recognizes a significant development potential for vafidemstat in psychiatric indications

PORTICO, a Phase IIb trial with vafidemstat in all-in BPD to treat agitation-aggression

❖ **PORTICO: a Phase IIb in BPD Under Preparation**

- double blind, randomized, placebo-controlled, 16-week treatment period
- Spain, US and Europe TBD
- N=100
- **Expected FPI: tbd (examining Covid-19 impact)**
- Expected LPO: tbd

❖ After positive data in REIMAGINE-AD, a Phase IIb in agitated-aggressive AD patients (GATEWAY*)* will be designed and prepared

❖ A personalized medicine Phase II trial in SetD1a mutant schizophrenic patients under study in collaboration with a Top US Institution

❖ A personalized medicine Phase II trial in Shank3 mutant Phelan McDermit (ASD) patients under study in collaboration with one of the most important Hospitals in Spain

OPTIONS TO ACCELERATED APPROVAL IN GENETICALLY DEFINED SUBPOPULATIONS OF SCZ AND ASD

An ambitious Phase II trial, ETHERAL: Epigenetic THERapy in ALzheimer's Disease

Besides aggression, vafidemstat may provide also further benefits to AD patients

Phase IIa study to provide useful information to design future Phase II/III studies



- ✓ **150 Mild to Moderate AD** patients (6+6 months)
- ✓ Primary Objective: Safety & Tolerability
- ✓ Secondary Objectives:
  - ✓ Cognition/Agitation/Apathy/ Depression/QoL
  - ✓ Volumetric MRI

- ✓ 17 sites; 117 patients
- ✓ Spain, France & UK
- ✓ **Recruitment finalized**

- ✓ Twin study in US: around 25-28 patients
- ✓ FPI recruited in May
- ✓ Recruitment ongoing

- ✓ **Biomarker guided study** (with different CSF Biomarkers: Anti-inflammatory, synaptic integrity and neurodegeneration markers)

ETHERAL-EU 6m data: Safety and PK/PD Results

- Vafidemstat treatment appears to be **safe and well tolerated**
  - Similar drop-outs in all arms
  - 23 SAEs observed were randomly distributed through study arms. Most of them (78%) not related to the drug treatment
  - Platelet, neutrophils and other hematological parameters do not show clinically relevant variations due to vafidemstat treatment
  - No abnormal and clinically significant liver enzymes levels or other laboratory findings reported to date
- Pharmacokinetic results correlate with previous observations (Phase I data)
- No MAO-B inhibition detected in the PBMCs of AD patients, as expected from Phase I data
- Vafidemstat acts as a selective LSD1 inhibitor in humans at the therapeutic doses tested



*One-tail Student t test (***, p<0.001; ns, not significant)*
LSD1-TE: LSD1 Target Engagement

Data Presented at APRIL 2020

AD/PD™2020
The 15th International Conference on Alzheimer's & Parkinson's Diseases

ETHERAL-EU 6m data: CSF Biomarkers – YKL40, neurogranin and NFL

Vafidemstat treatment reduces the levels of the inflammatory CSF biomarker YKL40

- After 6 month of treatment, a treatment effect on the CSF levels of the inflammatory **YKL40 biomarker** was observed, which appears mainly driven by the effect in moderate patients
- Although no statistically differences were observed between groups, a trend to reduce CSF neurogranin (NRGR) levels was observed in vafidemstat treatment arms, **achieving statistically significance in the low dose arm in moderate patients**
- Plasma neurofilament light chain (NFL) has been proposed as a blood-based biomarker for neurodegeneration; **in mild patients, vafidemstat treatment at 1.2 mg was able to reduce the increase of NFL**



Sub-analysis. One-way ANOVA not corrected by multiplicity in total, mild or moderate population) (ANOVA p value in blue, not showed when not significant) with Post-hoc multiple comparisons Tukey test (, p<0.05)*

ETHERAL-EU 6m data: Preliminary Cognitive Efficacy data - ADAS-Cog14

6 month analysis did not show cognitive improvement after vafidemstat treatment

- No statistically significant differences were expected or observed in the ADAS-Cog14 at 6 months between treatment arms
- No significant progression was seen through visits (change over time) in any of the treatment arms
- An unexpected improvement in the Placebo arm was observed (with improvements >10pts) and will require further analysis. This fact will difficult additional interpretations in terms of Cognition
- **65% of the Placebo patients showed an improvement in their ADAS-Cog14 score after 6 months of study duration**, some with increases of 10-20 points





Vafidemstat and inflammation: Decrease of YKL40 in humans in keeping with previous preclinical data

Vafidemstat treatment reduces the levels of the inflammatory marker YKL40 in brain and spinal chord in the EAE MS model

- **Chi3l3,** a member of the same family, **is strongly induced during the effector phase in the EAE model and was one of the gene most strongly reduced with vafidemstat, especially in the spinal cord.** The dose was 0.5 mg/kg of vafidemstat (ORY-2001).



ETHERAL-EU: 6 month Analysis - Key Findings Summary

- ETHERAL has met the Primary Safety Endpoint
  - *Vafidemstat was safe and well-tolerated in a mild-to-moderate AD population*
- ETHERAL has produced **interesting biomarker data** that deserve further exploration
  - *Significant reduction in the CSF levels of YKL40 (an anti-inflammatory biomarker)*
  - *Signals of Improvement in the levels of Neurogranin (a synaptic damage biomarker) and NFL*
    - ***First in human data supporting PHARMACOLOGICAL ACTIVITY IN THE BRAIN: vafidemstat treatment reducing CSF inflammatory biomarker***
- ETHERAL is not powered for efficacy analyses
  - *No differences observed between groups on the ADAS-Cog14*
  - *Unexpected improvement in the Placebo arm will hamper additional interpretation*
  - *Additional analyses of the other efficacy endpoints is currently underway*
- ETHERAL study is still ongoing and patients are to be treated up to 12 months
  - *Current analysis of all data should be considered preliminary*
  - *Final 12 month data release for the EU study expected by Q2 2021*

IADADEMSTAT a Phase II Clinical Stage Compound with a broad developability in oncology

LSD1 and cancer

- LSD1 is involved in different cancers and **in cancer stemness**
- **High levels of LSD1 often correlate with more aggressive forms of cancer and/or bad prognosis**
- **Iadademstat** is a small molecule that selectively inhibits LSD1. Positive preclinical *in vivo* results in different xenograft models. Best in Class. Full characterization published in top-rank journal.

POTENTIAL ONCOLOGICAL INDICATIONS:

MoA well characterized in SCLC, AML and Medulloblastoma

Iadademstat (ORY-1001): a potent & selective differentiating agent: Summary

Cancer Cell
Article

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

Tamara Maes,[1,6,*] Cristina Mascaró,[1] Iñigo Tirapu,[1] Angels Estiarte,[1] Filippo Ciceri,[1] Serena Lunardi,[1] Nathalie Guibourt,[1] Alvaro Perdones,[1] Michele M.P. Lufino,[1] Tim C.P. Somervaille,[2] Dan H. Wiseman,[2] Cihangir Duy,[3] Ari Melnick,[3,4] Christophe Willekens,[5] Alberto Ortega,[1] Marc Martinell,[1] Nuria Valls,[1] Guido Kurz,[1] Matthew Fyfe,[1] Julio Cesar Castro-Palomino,[1] and Carlos Buesa[1]
[1]Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornellà de Llobregat, Spain
[2]Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK
[3]Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, 10065 NY, USA
[4]Department of Pharmacology, Weill Cornell Medicine, New York, 10065 NY, USA
[5]Drug Development Department (DITEP) and Hematology Department, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France
[6]Lead Contact
*Correspondence: tmaes@oryzon.com
https://doi.org/10.1016/j.ccell.2018.02.002



- Irreversible, highly selective, potent, small molecule LSD1 inhibitor. Covalently binds to FAD-cofactor of LSD1
- Orally bioavailable, good pharmacologic properties, ADME, PK
- Encouraging results in a **FiM Acute Leukemia Phase I/IIa trial**:
  - Administered to 41 Relapsed Refractory Acute Leukemia patients

Phase I/IIa acute leukemia – final data (*Manuscript submitted*)

- Safe and well tolerated: a meaningful candidate for combination with other agents
- Clear differentiating activity at molecular and cellular level
- Antileukemic activity observed in 29% of patients (12/41), including one **CRi** as proof of Biological concept

ALICE: An AML trial with LSD1i in Combination with azacitidine in the Elderly

A Phase IIa study to evaluate the safety, tolerability, dose finding and efficacy of iadademstat (ORY-1001) in combination with azacitidine in older patients with AML in first line therapy

✓ Single arm & Open label. Up to 36 patients to be enrolled. **Primary endpoint**: Safety and tolerability of the combo with hypomethylating agent Azacitidine. **Secondary endpoints:** Responses; time to responses; duration of response; and overall survival. Preliminary data for first 6 and 12 patients reported at **EHA-2019 & ASH-2019**

- **Combination of iadademstat and azacitidine shows a good safety profile in elderly AML patients**
- **Preliminary signals of clinical efficacy are encouraging, with 75% of ORs (6/8 evaluable patients: 2 CR, 3 CRi and 1 PR)**
- **Rapid clinical responses (mean time to first response is currently 32 days)**
- **Preliminary rate of conversion to red cell Transfusion Independence (40%) is also encouraging**



Iadademstat a therapeutic approach for SCLC with a well defined MoA

- ✓ LSD1 is a **target well characterized in SCLC**
- ✓ LSD1 inhibitors are effective in several in-vitro and in-vivo models of SCLC
- ✓ Characterized MoA
- ✓ Iadademstat produces **complete and durable tumor regression** in different **chemoresistant PDX models**
- ✓ Iadademstat is **efficacious in combos with CbEt and other agents**
- ✓ Identified and patented Biomarkers that are differential in sensitiveness to LSD1i
- ✓ Phase II trial ongoing in second line SCLC patients using these **biomarkers to stratify patients and identify super-responders**



Iadademstat is efficacious in monotherapy in some PDX-SCLC xenografts

- Response to iadademstat in PDX models of SCLC is variable, but some are very strong

- FHSC04 model: derived from a SCLC patient who relapsed after first line therapy
- **6/10 FHSC04 mice treated with iadademstat did not show relapse after 300 days**



Sci Signal. 2019 Feb 5;12(567).





FRED HUTCHINSON CANCER RESEARCH CENTER
A LIFE OF SCIENCE

Iadademstat: SCLC - Phase II CLEPSIDRA - preliminary efficacy signals

CLEPSIDRA: A **C**ombination trial of **L**SD1 and **E**top-**P**latinum in **S**mall Cell Lung Cancer in **biomarker-ID** **R**elapsed p**A**tients

A Phase IIa study to assess the safety, tolerability, dose finding and efficacy of iadademstat (ORY-1001) in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancer who are positive to candidate predictive biomarkers

- Single arm
- Open label; 6 sites in Spain
- **Up to 36 patients to be enrolled**
- **4-6 cycles iadademstat+platinum/etoposide, thereafter iadademstat monotherapy (at investigators' criteria)**
- **Primary endpoint**: Safety and tolerability of the combo with platinum-etoposide therapy
- **Secondary endpoints:** RECIST responses; time to responses; duration of response; and overall survival



Biomarker analysis from a CLEPSIDRA patient

Iadademstat: SCLC - Phase II CLEPSIDRA - preliminary efficacy signals

Preliminary Results

IASLC 2019 World Conference on Lung Cancer, September 7-10, 2019 | Barcelona, Spain

BARCELONA 2019 ESMO congress



- **75% response rate** (6/8 evaluable patients): 4 PRs and 2 long-term SD
- Current level of observed responses suggests that **patient selection by Biomarkers** may be effective to increase ratio of ORs



Patient 1	cycle 1	cycle 2	cycle 3	cycle 4	cycle 5	cycle 6	cycle 7	cycle 8	cycle 9	cycle 10	cycle 11	cycle 12	cycle 13
CbEp													
iadademstat	60	60	60	60	60	60	60	60	60	60	60	60	60
Best response			PR -43,30%		PR -71,20%		PR -78,70%		PR -86,30%		PR -86,30%		PR -86,30%

- Main toxicity observed in the combination with carboplatin-etoposide is hematological
- **Iadademstat alone** is **safe** and **shows no hemato-logical, general or neuronal toxicity** in ED-SCLC patients, suggesting potential for monotherapy and other combos
- Iadademstat alone sustains further therapeutic benefit

Anticipating a rich flow of science catalysts / clinical data (non-comprehensive selection)

Iadademstat Phase IIs in oncology

CLEPSIDRA

ALICE

2020

June (virtual meeting)

EHA EUROPEAN HEMATOLOGY ASSOCIATION

ALICE AML data

Madrid – September

MADRID 2020 ESMO congress

CLEPSIDRA SCLC data

San Diego – December

AMERICAN SOCIETY OF HEMATOLOGY

ALICE AML data

2021

REIMAGINE-AD
ETHERAL-EU 6m Interim

April

ETHERAL-US
6m Interim

AD/PD™ 2021
The 15th International Conference on Alzheimer's & Parkinson's Diseases

Barcelona - March

ETHERAL-EU+US
12m FINAL

alzheimer's association AAIC 21

Boston - June

Vafidemstat Phase IIs in CNS

REIMAGINE-AD

ETHERAL

SATEEN

PORTICO

Potential Conferences where data may be presented

ORYZON – a unique investment opportunity in an epigenetic platform

- A differential proposition in **EPIGENETICS** drugs in **CNS and ONCOLOGY** around one of the most interesting targets in the field: **LSD1**
- **2 molecules** in **Phase II** with promising clinical signals of efficacy in patients
- **Pioneers in CNS epigenetics**
  - Vafidemstat shows efficacy in psychiatric disorders (BPD , ADHD, ASD)
  - **Phase IIb in Borderline personality disorder in preparation**. Additional trials in agitation in AD, ADHD or ASD under evaluation
  - Vafidemstat may be also clinically relevant in neurodegenerative disorders (Phase IIs in MS and AD ongoing)
  - Trials in genetically defined patient subpopulations in SCZ and ASD under study
- **Most advanced** LSD1i (iadademstat) **in Oncology**
  - **Positive preliminary efficacy results** reported in the ongoing Phase II trials in AML and SCLC
  - **SCLC trial is a biomarker-guided** study to stratify responsive patients
  - Options to get accelerated approval
- **Rich pipeline** of clinical **news** expected in the next Qs. Clinical Operations in US started and under expansion
- A **cash efficient** company with a seasoned international management team
- **€135M market cap**. One of the most liquid stocks in the microcap group in MadridSEXC with **plans to** get dual listed in **NASDAQ**
- Perseverant **presence in the US market in the last 4 years**. Three successful PIPEs executed in 2017-19 led by US Investment Banks and with participation of US-EU-IL investors

ORYZON

Pioneering Personalized Medicine in

EPIGENETICS